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Abstract Cystatin B and signal transducer and activator of
transcription-1 (STAT-1) phosphorylation have recently
been shown to increase human immunodeficiency virus-
1 (HIV-1) replication in monocyte-derived macrophages
(MDM), but the molecular pathways by which they do
are unknown. We hypothesized that cystatin B inhibits
the interferon (IFN) response and regulates STAT-1
phosphorylation by interacting with additional proteins.
To test if cystatin B inhibits the IFN-β response, we
performed luciferase reporter gene assays in Vero cells,
which are IFN deficient. Interferon-stimulated response
element (ISRE)-driven expression of firefly luciferase
was significantly inhibited in Vero cells transfected with
a cystatin B expression vector compared to cells
transfected with an empty vector. To determine whether
cystatin B interacts with other key players regulating
STAT-1 phosphorylation and HIV-1 replication, cystatin
B was immunoprecipitated from HIV-1-infected MDM.
The protein complex was analyzed by liquid chroma-
tography tandem mass spectrometry. Protein interactions
with cystatin B were verified by Western blots and
immunofluorescence with confocal imaging. Our find-
ings confirmed that cystatin B interacts with pyruvate
kinase M2 isoform, a protein previously associated
cocaine enhancement of HIV-1 replication, and major
vault protein (MVP), an IFN-responsive protein that
interferes with JAK/STAT signals. Western blot studies
confirmed the interaction with pyruvate kinase M2
isoform and MVP. Immunofluorescence studies of
HIV-1-infected MDM showed that upregulated MVP
colocalized with STAT-1. To our knowledge, the current
study is the first to demonstrate the coexpression of
cystatin B, STAT-1, MVP, and pyruvate kinase M2
isoform with HIV-1 replication in MDM and thus
suggests novel targets for HIV-1 restriction in macro-
phages, the principal reservoirs for HIV-1 in the central
nervous system.




CAF CD8 T lymphocyte antiviral factor
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Monocytes, macrophages, and microglia are mononuclear
phagocytes important in innate immunity and also key
reservoirs of human immunodeficiency virus-1 (HIV-1) in
the central nervous system (CNS). These reservoirs present a
challengetoHIVeradication astheycontinuetoproduce virus
in tissue despite antiretroviral therapy. Our group recently
showed that cystatin B, a cysteine protease inhibitor, is
upregulated in blood monocyte-derived macrophages
(MDM) compared to placental macrophages, which are less
susceptiblethanMDMtoHIV-1infection(Luciano-Montalvo
et al. 2008). Intracellular expression of cystatin B was
increased in HIV-1-infected MDM at 12 days post-infection
(Luciano-Montalvo et al. 2008) and in the secretome of HIV-
1-infected MDM (Ciborowski et al. 2007;G a r c i a - C r e s p oe t
al. 2009), suggesting that this protein is activated during HIV
infection. A direct connection between cystatin B and HIV
replication was demonstrated using small interfering RNA
against cystatin B (Luciano-Montalvo et al. 2008). Subse-
quently, the signaling mechanisms for cystatin B in HIV
replication were related to its interaction with signal
transducer and activator of transcription-1 (STAT-1)
(Luciano-Montalvo and Melendez 2009). Whereas STAT-1
activates HIV-1 replication, high levels of tyrosine phos-
phorylated STAT-1 (STAT-1PY) have been associated with
HIV-1 inhibitory activity (Chang et al. 2002). Interestingly,
recent data from our laboratory using more specific
monoclonal antibodies showed higher levels of STAT-1PY
in placental macrophages, a cell that restricts HIV replica-
tion, than in MDM (Luciano-Montalvo and Melendez 2009),
and very low levels in MDM until 12 days after infection.
Low levels of cystatin B together with high levels of STAT-
1PY may restrict HIV replication in placental macrophages,
whereas high levels of cystatin B and low levels of STAT-
1PY may promote HIV replication in MDM (Luciano-
Montalvo and Melendez 2009). However, the signaling
pathways and mechanisms for increased HIV-1 replication
in MDM are yet to be determined.
Although cystatin B is recognized primarily as a cysteine
proteaseinhibitorratherthanaregulatoryprotein,DiGiamoet
al. identified five recombinant proteins that interact with
cystatinB,noneofwhichisa protease(Di Giamo etal. 2002).
Those investigators suggested a role of the cystatin B
multiprotein complex in the cerebellum; disruption of which
correlated with the etiology and pathogenesis of progressive
myoclonus epilepsy, a degenerative disease of the central
nervous system. That was the first time cystatin B was
reported to be part of a multiprotein complex with an
unknown function. In the present study, we identified
proteins interacting with cystatin B in order to elucidate the
relationship between this protein, STAT-1 phosphorylation,
and HIV-1 replication in MDM.
Type I interferons α and β (IFN-α and IFN-β)a r e
antiviral proteins important in innate immunity. The
production of IFN-β is a rapid and very effective
antiviral response to HIV in cultured macrophages
(Gessani et al. 1994a, b). In the present study, we found
that cystatin B inhibited the IFN-β response in Vero cells
by preventing STAT-1 translocation to the nucleus and
decreasing levels of STAT-1PY. The discovery of this
mechanism of cystatin B regulation of STAT-1 phosphor-
ylation could inform the development of new therapeutic
approaches that aim to inhibit the long terminal repeat
(LTR)-mediated HIV replication by modulating the site of
STAT-1 phosphorylation in favor of tyrosine instead
inhibiting STAT-1 expression.
Results
Proteins associated with cystatin B To determine whether
cystatin B interacts with other key players regulating STAT-
1 phosphorylation and HIV-1 replication, cystatin B was
immunoprecipitated from HIV-1-infected MDM as de-
scribed previously (Luciano-Montalvo and Melendez
2009), and the protein complex was analyzed by liquid
chromatography tandem mass spectrometry (LC-MS/
MS). We found that cystatin B interacts with many
different proteins in HIV-1-infected cells, including
regulatory, glycolytic, metabolic, structural, transport,
proteases, and immune proteins (Table 1). Most of the
proteins identified (25 of 37) associated with cystatin B in
HIV-1-infected cells but not in uninfected controls. Two
proteins did not associate with cystatin B in HIV-infected
cells, but did so in uninfected controls: cathepsin B (a
cysteine protease inhibited by cystatin B) and elongation
factor 1. Bound proteins were not detected in the negative
control, pre-cleared MDM lysates incubated with uncon-
jugated beads.
Validation of immunoprecipitated proteins Major vault
protein (MVP), and pyruvate kinase M2 (PKM2) were
selected for validation by Western blot after co-
immunoprecipitation with cystatin B antibody because
these proteins are known to be involved in the regulation
of STAT-1 phosphorylation and HIV-1 replication. Western
blot studies confirmed that cystatin B interacted with
PKM2 isoform, a protein previously associated with
cocaine enhancement of HIV-1 replication, and MVP, an
IFN-responsive protein that interferes with IFN-activated
JAK/STAT signals (Fig. 1).
Studies of HIV-infected and uninfected MDM using
immunofluorescence and confocal imaging demonstrated
overexpression of MVP in HIV-infected cells (Fig. 2).
These results extend those of Steiner et al. (2006), who
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cells induced by IFN-γ. To our knowledge, the current
study is the first to demonstrate the coexpression of STAT-1
and MVP in HIV-1-infected MDM.
Cystatin B inhibition of IFN-β response in Vero cells To
test if cystatin B inhibits the IFN-β response, we performed
luciferase reporter gene assays in Vero cells, which are IFN
deficient. Robust IFN stimulation of gene 54 (ISG54)-
Table 1 Cystatin B-associated
proteins from HIV-1-infected
MDM and uninfected controls
Protein name Accession Molecular # peptide
UniProt Weight (Da) Control HIV +
Regulatory proteins
Major vault protein Q14764 99,326.3 3 14
Lymphocyte-specific protein 1 P33241 37,191.3 0 2
Glycolytic enzymes
Pyruvate kinase M1/M2 P14618 57,936.6 4 6
Human alpha-enolase P06733 47,168.7 0 6
Glyceraldehyde-3 phosphate dehydrogenase P04406 36,053.0 0 5
L-lactate dehydrogenase A P00338 36,688.5 0 2
Fructose-1,6-bisphosphatase 1 P09467 36,814.2 0 4
Metabolic proteins
Peroxisomal multifunctional enzyme type 2 P51659 79,685.9 0 2
Sulfide: quinoneoxidoreductasemitochondrial Q9Y6N5 49,960.4 0 5
Transketolase P29401 65,333 0 2
Heat shock protein HSP90 alpha P07900 84,659.1 0 2
V-type proton ATPase subunit B, brain isoform P21281 56,500.4 0 2
ATP synthase subunit alpha, mitochondrial P25705 59,750.3 0 3
Synaptic vesicle membrane protein VAT-1 homolog Q99536 41,920 0 3
Structural proteins
Elongation factor 1 P68104 50,140.5 2 0
Annexin A2 P07355 38,603.8 4 8
Myosin 9 (MYH9) P35579 226,529.8 5 36
Actin Cytoplasmic 1/2 P63261 41,736.5 5 9
Vimentin P08670 53,651.3 2 9
Macrophage-capping protein P40121 38,517.3 2 5
Cofilin-1 P23528 18,502.4 0 2
Plastin-2 P13796 70,288.9 4 11
Myosin regulatory light chain P05976 21,145 0 4
Moesin P26038 67,819.5 0 4
Protein disulfideisomeraseA6 Q15084 48,121 6 2
Human Filamin-A P21333 280,735.4 0 6
Gelsolin P06396 85,696.9 0 3
Ras GTPase- activating-like protein P46940 189,252 0 8
Alpha-actinin-1 P12814 103,056.9 0 2
Protein S100-A11 P31949 11,740.4 0 2
Transport-related proteins
Clathrin heavy chain 1 Q00610 191,612.6 6 3
ADP-ribosylation factor 1/3 Q9NZ52 20,696.6 0 2
Transferrin receptor protein 1 Q5RDH6 84,871 0 2
Proteases
Cathepsin B P07858 37,822 2 0
Cathepsin D P07339 44,552 0 2
Immune protein
HLA class I histocompatibility antigen P30488 45,000 0 2
22 J. Neurovirol. (2012) 18:20–29driven expression of firefly luciferase was seen in cells
transfected with an empty vector, and this stimulation was
abolished in cells transfected with a cystatin B vector (Fig. 3).
Furthermore, the interferon response of IFN-β-treated Vero
cells expressing cystatin B was significantly inhibited as
compared with the results before IFN treatment.
Inhibition of STAT-1 nuclear translocation and tyrosine
phosphorylation in response to cystatin B We used immu-
nofluorescence and confocal imaging on Vero cells tran-
siently transfected with a vector expressing cystatin B to
determine if this protein alters nuclear translocation of
STAT-1. Vero cells transfected with an empty vector or a
vector expressing NIPAH-V were used as negative and
positive controls, respectively. NIPAH-V was used because
it is known to inhibit the IFN-β response via inhibition of
STAT-1 translocation to the nucleus (Rodriguez et al. 2002).
Before IFN-β treatment, all STAT-1 immunoreactivity was
localized to the cytosol. STAT-1 immunoreactivity was
translocated to the nucleus after IFN-β treatment in the
negative empty control, but retained in the cytoplasm of the
NIPAH-V control, and in Vero cells expressing cystatin B
(Fig. 4).
The effect of cystatin B on the expression of STAT-1PY
was determined by Western blots (Fig. 5). Vero cells were
transfected with cystatin B plasmid for a period of 24 h.
Overexpression of cystatin B was demonstrated in trans-
fected cells with cystatin B vector after normalization with
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (*p<
0.05) (Fig. 5a, b). Cystatin B inhibited STAT-PY in Vero
cells (*p<0.05) (Fig. 5a, c). When IFN was added to cultures
in presence of cystatin B, there was a reduction in STAT-PY
relative to cystatin B-untreated cells that approached signif-
icance (p=0.06) (Fig. 5a, c). These results demonstrated that
cystatin B inhibits the IFN-β response and the nuclear
translocation of STAT-1 and a tendency to decreases the
expression of STAT-1PY in Vero cells.
Discussion
HIV-1-associated neurocognitive disorders result from HIV-
1 infection of the brain, alterations in the blood–brain
barrier, migration of activated monocytes, and a subsequent
induced immune activation response. HIV-1 replication and
neurotoxicity are both related to the type of STAT-1
phosphorylation. STAT-1 serine phosphorylation (STAT-
1PS) promotes blood–brain barrier damage (Chaudhuri et
al. 2008), whereas STAT-1PY has been associated with
HIV-1 inhibitory activity (Chang et al. 2002). Cystatin B
has been associated with decreased levels of STAT-1PYand
increased HIV-1 replication in MDM (Luciano-Montalvo
and Melendez 2009). However, the pathways and the
Fig. 1 Validation of immunoprecipitated proteins by Western blot.
MVP, and PKM2 were selected to be validated by Western blot after
co-immunoprecipitation with cystatin B antibody because they are
involved in the regulation of STAT-1 phosphorylation and HIV-1
replication. CSTB cystatin B; U87 U87 whole cell lysates used as
positive controls; C- controls for non-specific binding using uncon-
jugated beads and MDM lysates; HIV-1 + MDM lysates inoculated
with HIV-1ADA, HIV-1 uninfected MDM lysates
Fig. 2 Overexpression of MVP
in HIV-1-infected MDM at
12 days post-infection. Immu-
nofluorescence and confocal
imaging confirmed that MVP-
STAT coexpression is increased
in HIV-1-infected MDM. Con-
trol uninfected MDM; HIV-1 +
HIV-1-infected MDM at 12 days
post-infection. Green fluores-
cence represents MVP and red
fluorescence represents STAT-1
J. Neurovirol. (2012) 18:20–29 23mechanisms by which cystatin B interacts with STAT-1 are
unknown. Recently, cystatin B has also been shown to
interact with cathepsin B in HIV-negative macrophages but
fails to interact in HIV-negative MDM (Rodriguez et al.
2010). More recently, our group found that cystatin B also
fails in protecting against HIV-1 neuropathogenesis by lack
of inhibition of the cysteine protease cathepsin B, a potent
neurotoxin. In this study, we provide evidence that cystatin
B interacts with many different proteins in HIV-1-infected
MDM, indicating that cystatin B performs other functions
in addition to inhibiting cysteine protease. Furthermore, our
results demonstrated that cystatin B inhibits the IFN-β
response and inhibits the nuclear translocation of STAT-1
and demonstrated a tendency to decreases the expression of
STAT-1PY in Vero cells.
Ourfindingssupport thehypothesisthat cystatin Binteracts
with proteins related to HIV-1 replication. Five enzymes
associated with the glycolytic pathway, including the PKM2
isoform, were identified as cystatin B-associated proteins.
PKM2 has been reported to be upregulated in association with
cocaine enhancement of HIV-1 replication in normal human
astrocytes (Reynolds et al. 2006). In contrast, PKM2 is
downregulated in HIV-1/vesicular stomatitis virus-infected
murine microglia (Wang et al. 2008). This downregulation of
PKM2 occurs in parallel with the low levels of cystatin B
associated with HIV-1 restriction in microglia (manuscript in
revision). Cystatin B also seems to interact with proteins
involved in the regulation of STAT-1 phosphorylation. One of
these proteins is MVP, the main component of vaults. Vaults
are large ribonucleoprotein particles implicated in the
regulation of cellular signaling cascades and may act as
scaffolds for proteins involved in signal transduction. The
vaults are composed of three proteins: MVP, the telomerase-
associated protein and the vault poly (ADP-ribose) polymer-
ase. MVP has multiple roles in signal pathway regulation and
immunity (Berger et al. 2009) and is associated with PTEN
and PI3K (Yu et al. 2002), ERK and EGFR/SHP2/MAPK/Src
(Kolli et al. 2004), multidrug resistance (Kitazono et al. 1999,
2001), and proteins associated with the ubiquitin pathway as
C O P 1( Y ie ta l .2005). In addition to all these functions,
MVP is an IFN-γ-responsive gene that interferes with the
IFN-γ-induced antiviral response mediated by STAT-1
signaling (Steiner et al. 2006). Using tandem mass spectrom-
etry, we found that MVP is also associated with cystatin B. In
the present study, STAT-1 was not detected among the
proteins associated with cystatin B by mass spectrometry.
However, the co-immunoprecipitation of cystatin B and
STAT-1 in HIV-infected MDM was previously demonstrated
by our group using direct Western blot detection of STAT-1 in
the cystatin B-immunoprecipitated pool of proteins (Luciano-
Montalvo and Melendez 2009). A possible explanation for
the absence of STAT-1 in the IP LC-MS/MS analysis could
be poor ionization of these peptides, masking by other
ionized peptides, or data that did not pass our conservative
Fig. 3 Cystatin B inhibition of IFN-β response in Vero cells. Interferon
stimulation of gene 54 (ISG54)-driven expression of firefly luciferase
was significantly inhibited in cells transfected with a cystatin B vector
compared to cells transfected with the empty vector. a Plasmid construct
containing the ISG54 promoter fused to firefly luciferase and the SV40
promoter fused to Renilla luciferase. b Vector used to induce expression
of cystatin B. c Luciferase reporter gene assays in Vero cells. Cells were
transiently transfected with an empty vector (mock) or a vector
expressing cystatin B (Cst B) and stimulated with 500 U/mL IFN
(IFN+)o rl e f tu n t r e a t e d( IFN−). Twenty-four hours posttreatment, the
cells were lysed and the luciferase activity was measured by using a
dual luciferase assay (Promega). Firefly luciferase units were divided by
Renilla units to obtain relative luciferase units (RLU). Mean of four
independent experiments, *p<0.05. Error bars represent ±SEM
24 J. Neurovirol. (2012) 18:20–29exclusion criteria. The LC-MS/MS data are conservatively
analyzed to accept as positive identifications only those data
that pass these exclusion criteria: BioWorks® unified score
of >3,000, Xcorr for doubly charged precursor ion of >2.5,
DeltaCn of >0.3, more than 60% of fragment ions per
sequenced peptide, and at least two peptides per protein for
identification.
Interestingly, the othercystatinB-associated protein related
to HIV-1 replication, PKM2, is co-regulated at the gene and
protein level by STAT-1 (Pitroda et al. 2009) and is a
phosphotyrosine-binding protein that binds directly and
selectively to tyrosine-phosphorylated peptides (Christofk et
al. 2008). In the present study, the MVP and PKM2 proteins
were chosen for verification by Western blot because they
have been reported in the literature as being involved in HIV-
1 replication and the regulation of STAT-1 phosphorylation.
The presence of both protein bands was confirmed in
Western blots of HIV-infected MDM. Furthermore, immuno-
fluoresence and confocal imaging demonstrated increased
the expression of MVP that colocalized with STAT-1 in HIV-
1-infected MDM, as was reported earlier for tumor cells
(Steiner et al. 2006). To our knowledge, this is the first study
to demonstrate the coexpression of cystatin B and MVP with
HIV-1 replication in MDM. This finding points to these
proteins as potential novel targets for anti-HIV therapy in
macrophages, the principal reservoirs for HIV-1 in the CNS.
Future studies will elucidate the exact role that cystatin B
interactions with MVP and PKM2 play in STAT-1 phos-
phorylation and HIV replication in MDM.
Both neurotoxicity and HIV replication are related to the
type of STAT-1 phosphorylation. STAT-1PS is detrimental
in that it promotes blood–brain barrier damage (Chaudhuri
et al. 2008), whereas STAT-1PY is beneficial as it has been
associated with HIV-1 inhibitory activity mediated by CD8
T lymphocyte antiviral factor (CAF) (Chang et al. 2002).
CAF inhibits LTR-mediated HIV replication by inducing
the expression of interferon regulatory factor 1 (IRF-1),
which is STAT-1PY dependent. STAT-1 inhibition has been
suggested as a new therapeutic approach to clear HIV-1
macrophage reservoirs (Magnani et al. 2003). Taking these
data together, we propose that preventing viral replication
in macrophages might be accomplished by modulating the
site of STAT-1 phosphorylation in favor of tyrosine, as it is
known that STAT-1PY inhibits LTR-mediated HIV replica-
tion. We also postulate that cystatin B may inhibit the
signaling pathway mediated by IFN-β by regulating STAT-
1 tyrosine phosphorylation. This action would prevent the
expression of IFN-dependent antiviral genes and promote
HIV replication mediated by LTR and IRF-1. To test if
cystatin B inhibits the IFN-β response, we performed
luciferase reporter gene assays in Vero cells, which are IFN
deficient. ISG54-driven expression of firefly luciferase was
significantly inhibited in Vero cells expressing cystatin B
relative to cells transfected with the empty vector (Fig. 3).
These findings allow us to propose two mechanisms for the
high levels of HIV replication in MDM mediated by
cystatin B: (1) a decrease in IFN-β-induced antiviral gene
expression mediated by the STAT-1/IRF-1 complex and (2)
an induction of HIV replication mediated by the NF-Kβ/
IRF-1 complex.
Following cellular activation, the binding of cellular
transcription factors such as NF-kβ to response elements in
the HIV-1 promoter results in marked upregulation of HIV
replication (Kinoshita et al. 1997). NF-kβ transcriptional
activity requires the IRF-1 to induce HIV replication by
formation of a complex at the HIV-1 LTR. The NF-kβ/IRF-1
complex binds to the gene promoter and induces HIV
replication (Sgarbanti et al. 2008). Furthermore, NF-kβ
suppresses both antiviral and immunomodulatory actions of
IFN-β against influenza virus (Wei et al. 2006), whereas in
NF-kβ knockout mice, IFN-β induced the binding of STAT-
1 and IRF-1 to activate genes (Wei et al. 2006). STAT-1PY
has been associated with HIV-1 inhibitory activity (Chang et
al. 2002) and recent studies by our group showed that
cystatin B is associated with a reduction in STAT-1PY and
Fig. 4 Inhibition of nuclear translocation of STAT-1 by cystatin B
expression. Immunofluorescence and confocal imaging of Vero Cells
transiently transfected with a vector expressing cystatin B shows that
cystatin B alters the nuclear translocation of STAT-1 after treatment
with 500 U/mL IFN-β. Vero cells transfected with an empty vector
(control) or a vector expressing NIPAH-V were used as negative and
positive controls, respectively. Blue fluorescent DAPI nucleic acid
stain was used as nuclear stain
J. Neurovirol. (2012) 18:20–29 25HIV replication in MDM (Luciano-Montalvo and Melendez
2009), and together these findings provide support for a role
of cystatin B in HIV replication. On the basis of our results
and a review of relevant literature, we propose a mechanism
to explain how cystatin B promotes viral replication in
macrophage reservoirs (Fig. 6). We propose that the
reduction of STAT-1PY prevents the formation of the
STAT-1PY/IRF-1 complex, thus inhibiting the expression
of antiviral genes induced by IFN-β. The induction of IRF-1
expression by IFN-β (Fujita et al. 1989) and its availability
due to low levels of STAT-1PY allows the formation of the
NFk-β/IRF-1 complex that induces LTR-mediated HIV
replication. Future studies will be aimed at elucidating the
role of cystatin B in regulating the JAK/STAT-1 pathway and
LTR-mediated HIV-1 replication in MDM and determining
whether cystatin B is a novel regulatory protein and if MVP
plays a role in this interaction. These studies may prove
important for the development of inhibitory therapeutic
directed against macrophage HIV reservoirs.
Materials and methods
Monocyte isolation, cultivation, and HIV-1 infection Per-
ipheral blood mononuclear cells were isolated from the
peripheral blood of healthy donors after appropriate con-
sents were obtained in accordance with the University of
Puerto Rico Medical Sciences Campus Institutional Review
Board protocol #0720109. The cells were seeded into T-25
flasks as adherent MDM cultures in RPMI media supple-
Fig. 5 Decreased levels of
STAT-1PY expression are asso-
ciated with cystatin B expres-
sion. The effect of cystatin B on
the expression of STAT-1PY
was determined by Western
blots. Vero cells were either
mock transfected or transfected
with cystatin B plasmid for a
period of 24 h. IFN-β (500 U/
ml) was added to the cultures.
Whole cell lysates were collect-
ed after 24 h of IFN exposure.
The expression of STAT-1PY
and cystatin B is shown in
presence and absence of IFN
(a). Overexpression of cystatin
B is demonstrated in cells
transfected with cystatin B vec-
tor after normalization with
GAPDH (*p<0.05) (b). Cells
transfected with cystatin B
demonstrated a decreased ratio
of STAT-1PY over cystatin B
and a tendency to decrease in
the presence of IFN-β (p=0.09)
(c). Control lanes represent cul-
tures that were not transfected
with a vector. This experiment is
representative of three biological
replicates
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100 U/mL pen/strep, and 2 mM glutamine. On day 7,
MDMs were exposed to HIV-1ADA stock using a multi-
plicity of infection of 0.1 by overnight incubation or left
untreated as negative controls. One day after exposure to
the virus, a full media exchange was performed; thereafter,
a half media exchange was done every 2 days. Supernatants
at 6, 9, and 12 days post-infection were collected to monitor
infection by HIV-1 p24 antigen ELISA (Express BioTech
International, Thurmont, MD) following the manufacturer’s
instructions. MDMs were maintained for 12 days in culture
and lysed on ice with lysis buffer [5 mM Tris–HCl buffer,
pH 8, 0.1% Triton X-100, and protease inhibitor cocktail
(Sigma, St. Louis, MO)].
Immunoprecipitation Monoclonal antibodies against cysta-
tin B (Sigma, St. Louis, MO) were used for protein-specific
immunoprecipitation from cell lysates using an Exacta
homologous IP/WB kit (Santa Cruz Biotechnology, Santa
Cruz, CA) as described previously (Luciano-Montalvo and
Melendez 2009). Whole cell lysates were pre-cleared by
immunoprecipitation with beads for 1 h, and the samples
were incubated with antibody-conjugated beads overnight
followed by several washes. The pre-cleared lysates were
incubated with unconjugated beads as controls for non-
specific binding. The U87 whole cell lysates were used as a
positive control for cystatin B.
LC-MS/MS Immunoprecipitated proteins were digested in
solutionbyanovernightincubationwith trypsin (0.1μg/μl)at
37°C. Peptides were extracted [60% acetonitrile with 0.1%
trifluoroaceticacid(TFA)],dried,andthenresuspended(0.5%
TFA) prior to purification using ZipTip® (Millipore Corpora-
tion, Billerica, MA). Peptides were resuspended in 2%
acetonitrile with 0.1% formic acid prior to fractionation on a
microcapillary RP-C18 column (New Objectives, Woburn,
MA). The peptides were then fragmented and sequenced
with a nanospray ionization configuration using a LTQ XL
MS/MS (ThermoElectron, Thermo Fisher Scientific,
Walthan, MA). The spectra obtained were searched against
UniProtKB/Swiss-prot.fasta indexed for human proteins
using the Turbo SEQUEST search engine (BioWorks 3.2).
Protein hits were subjected to exclusion criteria and accepted
as positive with high confidence if two or more unique
peptides were sequenced per protein. Immunoprecipitation
and protein identification experiments were performed with
two different cultures from different donors.
Western blot analyses The MDM-immunoprecipitated pro-
teins and Vero cell lysates were diluted with Laemmli sample
buffer (BioRad, Hercules, CA) applied to a 10% Tris–HCl
Ready Gel (BioRad, Hercules, CA) and transferred to 0.45-
μm nitrocellulose membranes (BioRad, Hercules, CA). After
blocking with 5% bovine serum albumin in Tris-buffered
saline, membranes were incubated with mouse anti-cystatin B
(1:500, Sigma, St. Louis, MO). MDM-immunoprecipitated
proteins were immunoblotted with mouse anti PKM2 (1:500,
Abcam, Cambridge, MA) and rabbit anti-MVP (1:100,
Abcam, Cambridge, MA). For immunoprecipitated proteins,
the U87 and HeLa cell lysates were used as positive control
for cystatin B. The Vero cells were immunoblotted with
mouse anti-STAT-1PY (1:500 Abcam, Cambridge, MA).
Empty vector was used as mock-transfected control and
untransfected cells as negative controls. Mouse GAPDH
(1:1,000) (Abcam) was used as the loading control. Signal
was detected using the Super Signal® West Femto Maximum
Sensitivity Substrate (Thermo). The density of protein bands
was determined using the VersaDoc Imaging System (BioRad
Laboratories, Hercules, CA) with Quantity One software and
normalized against GAPDH.
Immunofluorescence and confocal imaging of MDM Mo-
nocyte isolation, cultivation, and HIV-1 infection were
performed using the Lab-Tek Chamber Slides (Fisher,
Pittsburgh, PA) in adherent cultures. The MDMs were fixed,
permeabilized, and incubated overnight with anti-rabbit MVP
(1:100, Abcam, Cambridge, MA) and anti-mouse STAT-1
(1:500, Abcam, Cambridge, MA) primary antibodies, and for
1 h with ALEXA-conjugated secondary antibody (Invitrogen,
Carlsbad, CA). Confocal images were obtained on a Zeiss
LSM 5 confocal laser-scanning microscope.
Co-transfection and luciferase reporter gene assays Vero
cells, which are IFN deficient, were grown in minimum
essential medium (Invitrogen, Carlsbad, CA) containing
10% fetal bovine serum to reach 70–80% confluence. To
Fig. 6 Proposed mechanism for cystatin B stimulation of viral
replication in macrophage reservoirs. Cystatin B may regulate STAT-
1 phosphorylation and thus control LTR-mediated replication and
interferon-induced antiviral response, resulting in increased HIV
replication in macrophage reservoirs. The numbers indicate the
approach to be used to assess each step: (1) immunoprecipitation
followed by LC-MS/MS, (2) immunoprecipitation followed by
Western blot, (3) luciferase assay of IFN-treated and untreated Vero
cells, (4) as reported in the literature: 4a (Fujita et al. 1989); 4b
(Sgarbanti et al. 2008); 4c (Steiner et al. 2006)
J. Neurovirol. (2012) 18:20–29 27induce the expression of cystatin B, 7.5×10
5 cells were
seeded in 6-well plates and incubated overnight. Three
grams of Homo sapiens cystatin B as transfection-ready
DNA NM_000100.2 inserted in pCMV6-XL5 (OriGene,
Rockville, MD) or empty pcDNA3.1 vector was transfected
with Lipofectamine (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions, together with 1 g of a plasmid
construct containing the ISG54 promoter fused to firefly
luciferase and the SV40 promoter fused to Renilla luciferase
(provided by Dr. Muñoz). The cells were stimulated with
500U/mLofIFN-ß(PBLInterferonSource,Piscataway,NJ)in
Opti-MEM I Reduced Serum Medium (Invitrogen, Carlsbad,
CA) or left untreated. Twenty-four hours posttreatment, the
cells were lysed and the luciferase activity was measured via a
Triathler luminometer by using a dual luciferase assay
(Promega) as recommended by the manufacturer. Firefly
luciferase units were divided by Renilla units to obtain relative
luciferase units.
Immunofluorescence and confocal imaging of Vero Cells -
Vero cells were grown, co-transfected, and stimulated with
500 U/mL of IFN-β as described before. The Vero cells
were fixed, permeabilized, and incubated overnight with
anti-rabbit STAT-1 (1:500, Abcam, Cambridge, MA)
primary antibodies and for 1 h with ALEXA-conjugated
secondary antibody (Invitrogen, Carlsbad, CA). Blue-
fluorescent DAPI nucleic acid stain was used as the nuclear
stain. Confocal images were obtained on a Zeiss confocal
microscope Axiovert 200M with a LSM 510.
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